396 related articles for article (PubMed ID: 17641984)
1. [Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data].
Pascual AM; Boscá I; Escutia M; Bernat A; Coret F; Casanova B
Neurologia; 2008 Mar; 23(2):73-7. PubMed ID: 17641984
[TBL] [Abstract][Full Text] [Related]
2. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
Ozakbas S; Cagiran I; Ormeci B; Idiman E
J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.
Pascual AM; Boscá I; Coret F; Escutia M; Bernat A; Casanova B
Eur J Neurol; 2008 Mar; 15(3):284-8. PubMed ID: 18290849
[TBL] [Abstract][Full Text] [Related]
4. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
5. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
6. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
7. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.
Martinelli V; Rocca MA; Annovazzi P; Pulizzi A; Rodegher M; Martinelli Boneschi F; Scotti R; Falini A; Sormani MP; Comi G; Filippi M
Neurology; 2009 Dec; 73(22):1842-8. PubMed ID: 19949030
[TBL] [Abstract][Full Text] [Related]
8. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study.
Brochet B; Deloire MS; Bonnet M; Salort-Campana E; Ouallet JC; Petry KG; Dousset V
Mult Scler; 2008 Nov; 14(9):1242-9. PubMed ID: 18653737
[TBL] [Abstract][Full Text] [Related]
9. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
10. [Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].
Pokryszko-Dragan A; Bilińska M; Gruszka E; Dubik-Jezierzańska M
Pol Merkur Lekarski; 2005 Nov; 19(113):654-8. PubMed ID: 16498805
[TBL] [Abstract][Full Text] [Related]
11. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
Ostberg A; Pittas F; Taylor B
Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
[TBL] [Abstract][Full Text] [Related]
12. [Long-term application of the multiple sclerosis functional composite test in Debrecen, Hungary].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2006 Nov; 59(11-12):442-7. PubMed ID: 17203882
[TBL] [Abstract][Full Text] [Related]
13. [Randomized controlled trial of high-dose peroral methylprednisolone in attacks of multiple sclerosis].
Sellebjerg F; Frederiksen JL; Nielsen PM; Olesen J
Ugeskr Laeger; 1999 Nov; 161(48):6625-9. PubMed ID: 10643347
[TBL] [Abstract][Full Text] [Related]
14. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
16. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
[TBL] [Abstract][Full Text] [Related]
17. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis.
Patzold T; Schwengelbeck M; Ossege LM; Malin JP; Sindern E
Acta Neurol Scand; 2002 Mar; 105(3):164-8. PubMed ID: 11886358
[TBL] [Abstract][Full Text] [Related]
18. [Sleepiness and fatigue in multiple sclerosis - comparison of different measuring instruments].
Kotterba S; Eren E; Fangerau T; Malin JP; Sindern E
Fortschr Neurol Psychiatr; 2003 Nov; 71(11):590-4. PubMed ID: 14608510
[TBL] [Abstract][Full Text] [Related]
19. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
[TBL] [Abstract][Full Text] [Related]
20. [Application of the Multiple Sclerosis Functional Composite in Debrecen].
Mezei Z; Bereczki D; Csiba L; Csépány T
Ideggyogy Sz; 2005 Mar; 58(3-4):113-8. PubMed ID: 15887414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
